Schuller, Yvonne
Biegstraaten, Marieke
Hollak, Carla E. M.
Klümpen, Heinz-Josef
Gispen-de Wied, Christine C.
Stoyanova-Beninska, Violeta
Funding for this research was provided by:
College ter Beoordeling van Geneesmiddelen
Article History
Received: 8 December 2017
Accepted: 29 August 2018
First Online: 28 November 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: YS has no conflicts of interest. Over the past 3 years, MB has received travel support from Sanofi Genzyme once. MB and CH have not performed any paid consultancies nor received fees for speaking at conferences. The Academic Medical Center participates in clinical trials with Sanofi Genzyme and Protalix and received support for registries from Sanofi Genzyme and Shire HGT. None of the support or grants are related to the submitted work. Over the past 3 years, HJK received compensation for advisory board membership from IPSEN. His institution received research grant for a clinical trials from BAYER and Novartis.This publication is a summary of the European Public Assessment Reports and the summary of product characteristics available on the EMA website, focusing on the main issues discussed during the scientific evaluation. Healthcare professionals and interested readers are referred to the EMA website for up-to-date information on this marketing authorization (ExternalRef removed). The authors remain solely responsible for the opinions expressed in this publication.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.